If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReckitt Regulatory News (RKT)

Share Price Information for Reckitt (RKT)

Share Price is delayed by 15 minutes
Get Live Data
5,120.00    8.00 (0.16%)
Bid:
5,118.00
Ask:
5,120.00
Spread: 2.00 (0.039%)
Market Cap: £32.51b
RKT Live PriceLast checked at - London Stock Exchange

Intraday Reckitt Share Chart

Directorate Change

11 Aug 2022 10:27

RNS Number : 7266V
Reckitt Benckiser Group PLC
11 August 2022
 

11 August 2022

 

 

RECKITT BENCKISER GROUP PLC

DIRECTORATE CHANGE

 

Reckitt announces the appointment of

Jeremy Darroch as Non-Executive Director

 

 

Reckitt Benckiser Group plc today announces the appointment of Jeremy Darroch to the Board as a Non-Executive Director and member of the Remuneration Committee, effective 1 November 2022. It is the intention that, following a transition period, he will also succeed Nicandro Durante as the senior independent Non-Executive Director.

Jeremy is the former Executive Chairman and Group Chief Executive of Sky. Jeremy joined Sky PLC as Chief Financial Officer in 2004 and was promoted to Chief Executive Officer in 2007. He stepped down from this position in January 2021, becoming Executive Chairman until the end of that year and remains a senior advisor to the company. Prior to this, Jeremy was Group Finance Director of DSG International plc (formerly Dixons Group plc) and spent 12 years at Procter & Gamble in a variety of roles in the UK and Europe. Jeremy was previously senior independent Non-Executive Director and Chairman of the Audit Committee of Burberry Group plc, and Non-Executive Director and the Chairman of the Audit Committee of Marks and Spencer Group plc. He is also a WWF ambassador and the former Chairman of Business in the Community, the UK's oldest and largest responsible business network.

Commenting on the appointment, Chris Sinclair, Chair of the Board said:

"I am delighted that Jeremy has agreed to join the Reckitt Board. He is an outstanding leader, with considerable expertise in the consumer retail environment built up over a successful career at some of the UK's most high-profile companies. He has a proven track record of driving business performance and a unique insight into what motivates consumers, and we welcome the value he will bring to the Board."

The Company confirms that there is no further information to be disclosed under the requirements of Listing Rule 9.6.13R in relation to Jeremy Darroch's appointment.

 

 

For further Information:

Catheryn O'Rourke

Company Secretary

Tel +44 (0) 1753 217 800

 

 

Richard Joyce

Head of Investor Relations

Tel +44 (0) 7408 812 062

 

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

  

About Reckitt:

 

Reckitt* exists to protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. We believe that access to the highest-quality hygiene, wellness and nourishment is a right, not a privilege.

 

Reckitt is the company behind some of the world's most recognisable and trusted consumer brands in hygiene, health and nutrition, including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, Woolite and more.

 

Every day, more than 20 million Reckitt products are bought globally. We always put consumers and people first, seek out new opportunities, strive for excellence in all that we do and build shared success with all our partners. We aim to do the right thing, always.

 

We are a diverse global team of more than 43,000 colleagues. We draw on our collective energy to meet our ambitions of purpose-led brands, a healthier planet and a fairer society. Find out more, or get in touch with us at www.reckitt.com

 

*Reckitt is the trading name of the Reckitt Benckiser group of companies

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAGPUAPRUPPUBG
Date   Source Headline
13th Dec 202210:30 amRNSDirectorate Change
1st Dec 202212:00 pmRNSTotal Voting Rights
7th Nov 20222:57 pmRNSDirectorate Change
1st Nov 20222:55 pmRNSTotal Voting Rights
26th Oct 20227:00 amRNS3rd Quarter Results
20th Oct 20224:46 pmRNSHolding(s) in Company
3rd Oct 20222:43 pmRNSTotal Voting Rights
29th Sep 20224:59 pmRNSDirector/PDMR Shareholding
16th Sep 20222:54 pmRNSDirector/PDMR Shareholding
7th Sep 202212:00 pmRNSDirector/PDMR Shareholding
1st Sep 202210:55 amRNSTotal Voting Rights
1st Sep 20227:00 amRNSDirectorate Change
11th Aug 202210:27 amRNSDirectorate Change
5th Aug 202212:07 pmRNSDirector Declaration
1st Aug 20224:07 pmRNSTotal Voting Rights
27th Jul 20227:00 amRNSHalf-year Results
19th Jul 20229:41 amRNSDirector Declaration
1st Jul 20221:34 pmRNSTotal Voting Rights
13th Jun 202211:45 amRNSDirector/PDMR Shareholding
1st Jun 202212:37 pmRNSTotal Voting Rights
23rd May 20225:28 pmRNSDirector/PDMR Shareholding
20th May 20225:30 pmRNSResult of AGM
3rd May 202212:54 pmRNSTotal Voting Rights
29th Apr 20227:00 amRNS1st Quarter Results
27th Apr 20224:29 pmRNSNotice of AGM
14th Apr 202212:26 pmRNSAnnual Financial Report
1st Apr 20221:57 pmRNSTotal Voting Rights
22nd Mar 202212:18 pmRNSDirector/PDMR Shareholding
1st Mar 20223:39 pmRNSTotal Voting Rights
17th Feb 20227:00 amRNSReckitt FY 2021 Results
1st Feb 202210:32 amRNSTotal Voting Rights
17th Jan 20229:00 amRNSDirectorate Change
4th Jan 202211:21 amRNSTotal Voting Rights
24th Dec 20217:00 amRNSProposed Sale of E45 to Karo Pharma
1st Dec 202111:22 amRNSTotal Voting Rights
1st Nov 202111:47 amRNSTotal Voting Rights
26th Oct 202110:01 amRNSDirectorate Change
26th Oct 20217:00 amRNS3rd Quarter Results
4th Oct 20219:35 amRNSDirectorate Change
1st Oct 202111:15 amRNSTotal Voting Rights
23rd Sep 20217:00 amRNSTrading Update & Launch of Investor Seminar Series
16th Sep 20211:20 pmRNSDirector/PDMR Shareholding
9th Sep 20219:24 amRNSClosing sale of IFCN China business to Primavera
1st Sep 202111:08 amRNSTotal Voting Rights
31st Aug 20214:00 pmRNSDirector/PDMR Shareholding
4th Aug 202110:30 amRNSDirector/PDMR Shareholding
3rd Aug 20211:30 pmRNSDirector/PDMR Shareholding
2nd Aug 202112:50 pmRNSTotal Voting Rights
30th Jul 202110:57 amRNSDirector Declaration
29th Jul 20213:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.